ZYBT (Jilin Zhengye Biotechnology) Return on Gross Profit

ZYBT (Zhengye Bio) - company brandmark

Gross profit margins confirm the pricing power of Zhengye Biotechnology (ZYBT) within the veterinary vaccine sector, while the 20.50 mark reflects the current state of profitability. The development of biological products relies on a staff of high-caliber chemists and government grants. The business is currently stabilizing revenues following the completion of the agricultural cycle, optimizing costs to maintain sustainable operational strength amid global food demand.

ZYBT (Jilin Zhengye Biotechnology) Gross Profitability history from 01/08/2025 to 11/20/2026

Analytical breakdowns and data insights for company Zhengye Biotechnology (ZYBT)

Signature product of Zhengye Corp

Zhengye Biotechnology (ZYBT) holds a strong position in the veterinary biologicals segment, which is directly reflected in the gross margin chart. This indicator measures production efficiency by capturing the profit share after deducting direct costs, confirming the brand's ability to maintain pricing power due to the agricultural sector's high level of trust in vaccine quality.